Colgate-Palmolive Company
88.03USD
-0.3800 (-0.43%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.93▲ | $0.92 | 8 | 6 |
| Next quarter | $0.97▲ | $0.95 | 10 | 5 |
| Current year | $3.88▲ | $3.81 | 18 | 1 |
| Next year | $4.11▲ | $4.04 | 16 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.95 | $0.99 | +0.04 (+4.5%) |
| 2026-03-31 | $0.94 | $0.97 | +0.03 (+2.7%) |
| 2025-12-31 | $0.91 | $0.95 | +0.04 (+4.2%) |
| 2025-09-30 | $0.89 | $0.91 | +0.02 (+2.4%) |
325 ratings from 38 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| RBC Capital | Reiterated | Outperform | $104 | Sep 8, 2026 |
| UBS | Maintained | Buy | $106 $109 | Aug 3, 2026 |
| TD Cowen | Maintained | Hold | $85 $90 | Aug 3, 2026 |
| JP Morgan | Maintained | Overweight | $104 $103 | Aug 3, 2026 |
| RBC Capital | Maintained | Outperform | $102 $104 | Aug 3, 2026 |
| Evercore ISI Group | Maintained | Outperform | $100 $101 | Aug 3, 2026 |
| Barclays | Maintained | Equal-Weight | $80 $87 | Jul 21, 2026 |
| JP Morgan | Maintained | Overweight | $96 $104 | Jul 16, 2026 |
| UBS | Maintained | Buy | $100 $106 | Jul 16, 2026 |
| Citigroup | Maintained | Buy | $105 $110 | Jul 14, 2026 |
| Piper Sandler | Maintained | Overweight | $92 $96 | Jul 9, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $92 $95 | Jul 8, 2026 |
| Bernstein | Initiated | Market Perform | $96 | Jun 11, 2026 |
| Barclays | Maintained | Equal-Weight | $79 $80 | May 5, 2026 |
| JP Morgan | Maintained | Overweight | $95 $96 | May 4, 2026 |
| UBS | Maintained | Buy | $98 $100 | May 4, 2026 |
| RBC Capital | Reiterated | Outperform | $102 | May 4, 2026 |
| Morgan Stanley | Maintained | Overweight | $100 $95 | Apr 23, 2026 |
| Rothschild & Co | Upgraded from Neutral | Buy | $93 $100 | Apr 21, 2026 |
| JP Morgan | Maintained | Overweight | $97 $95 | Apr 17, 2026 |
| Barclays | Maintained | Equal-Weight | $88 $79 | Apr 14, 2026 |
| B of A Securities | Maintained | Buy | $105 $102 | Apr 10, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $100 $92 | Apr 8, 2026 |
| Piper Sandler | Maintained | Overweight | $96 $92 | Apr 8, 2026 |
| UBS | Maintained | Buy | $100 $98 | Apr 7, 2026 |
108 filings from 20 insiders · 17 buy / 5 sell over 6m
Officers and directors of CL, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| TSOURAPAS PANAGIOTISOfficer | Sellindirect | 10.0k | $92.05 | $920k | Aug 24, 2026 |
| CAHILL JOHN TDirector | Exercise | 4.2k | $71.56 | $298k | Aug 6, 2026 |
| CAHILL JOHN TDirector | Sell | 4.2k | $93.37 | $389k | Aug 6, 2026 |
| WALLACE NOEL RChief Executive Officer | Exercise | 322.0k | $72.29 | $23.28M | Aug 5, 2026 |
| WALLACE NOEL RChief Executive Officer | Sell | 322.0k | $91.92 | $29.70M | Aug 5, 2026 |
| NEWMAN BRIANDirector | Grant | 209 | $89.45 | $19k | Jul 1, 2026 |
| NORRINGTON LORRIE MDirector | Grant | 293 | $89.45 | $26k | Jul 1, 2026 |
| BILBREY JOHN P.Director | Grant | 265 | $89.45 | $24k | Jul 1, 2026 |
| MALCOLM GREGORYOfficer | Sell | 2.3k | $88.44 | $203k | May 15, 2026 |
| HARRIS C. MARTIN M.D.Director | Grant | 1.6k | — | — | May 11, 2026 |
| NEWMAN BRIANDirector | Grant | 2.1k | — | — | May 11, 2026 |
| NELSON KIMBERLY A.Director | Grant | 2.1k | — | — | May 11, 2026 |
| BOERNER CHRISTOPHER SDirector | Grant | 1.4k | — | — | May 11, 2026 |
| EDWARDS LISA MARIEDirector | Grant | 2.1k | — | — | May 11, 2026 |
| NORRINGTON LORRIE MDirector | Grant | 2.1k | — | — | May 11, 2026 |
| BILBREY JOHN P.Director | Grant | 2.1k | — | — | May 11, 2026 |
| HUND-MEJEAN MARTINADirector | Grant | 2.1k | — | — | May 11, 2026 |
| CAHILL JOHN TDirector | Grant | 2.1k | — | — | May 11, 2026 |
| MASSEY SALLYOfficer | Sell | 8.6k | $87.41 | $752k | May 7, 2026 |
| NEWMAN BRIANDirector | Grant | 210 | $89.05 | $19k | Apr 1, 2026 |
No analyst notes on CL yet.
Analyst Ratings
20 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 6 | 7 | 8 | 0 | 0 | Buy2.10 |
| 1 mo ago | 6 | 7 | 8 | 0 | 0 | Buy2.10 |
| 2 mo ago | 6 | 7 | 8 | 0 | 0 | Buy2.10 |